Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 137

Results For "FDA"

1717 News Found

Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Merck presents positive results from phase 1/2 study evaluating V116
News | June 22, 2022

Merck presents positive results from phase 1/2 study evaluating V116

V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019


Apollo Hospitals completes a procedure using new technology SENTINEL
Healthcare | June 16, 2022

Apollo Hospitals completes a procedure using new technology SENTINEL

Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.


EPR-Technologies announces new approach to emergency care when CPR fails
Healthcare | June 16, 2022

EPR-Technologies announces new approach to emergency care when CPR fails

EPR-Technologies is pursuing development of an unprecedented standard of emergency care when CPR fails


Dr. Reddy's Lab launches sorafenib tablets in US
News | June 15, 2022

Dr. Reddy's Lab launches sorafenib tablets in US

Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.


Piramal Pharma expands API capabilities at Digwal
News | June 15, 2022

Piramal Pharma expands API capabilities at Digwal

Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies


Philips announces positive research results from its TOBA II BTK clinical trial
Diagnostic Center | June 14, 2022

Philips announces positive research results from its TOBA II BTK clinical trial

First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization


Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis
Diagnostic Center | June 12, 2022

Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials


GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer
News | June 10, 2022

GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer

Healthcare is timely and personal – and its delivery should be too


Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis
Drug Approval | June 09, 2022

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.